RTI Biologics, Inc. (RTIX) Tops Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- US stock futures rise as investors assess Democrats' midterm sweep
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts RTIX Hot Sheet
Join SI Premium – FREE
RTI Biologics, Inc. (NASDAQ: RTIX) reported Q3 EPS of $0.05, $0.01 better than the analyst estimate of $0.04. Revenue for the quarter came in at $44.6 million versus the consensus estimate of $44.16 million.
For earnings history and earnings-related data on RTI Biologics, Inc. (RTIX) click here.
For earnings history and earnings-related data on RTI Biologics, Inc. (RTIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Uber (UBER) Tops Q3 EPS by 2c, Beats on Revenue; Offers Guidance
- Perrigo (PRGO) Tops Q3 EPS by 5c; offers guidance
- Timken (TKR) Tops Q3 EPS by 17c, Offers FY26 EPS Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
